Quantitative Insights

Quantitative Insights, Inc. (QI) was formed to realize the clinical and commercial value of QuantX, a Computer-Aided Diagnosis system to aid Radiologists in more accurate diagnosis of breast cancer. Developed in the labs and clinics of the University of Chicago to improve outcomes while, at the same time, significantly reducing costs, QuantX addresses critical needs of clinicians, practice administrators and patients.

The goal of quantitative insights is to provide the world’s first and only breast imaging decision support system with direct correlation to known pathology. Quantitative Insights is dedicated to improving patient management by harnessing the power of cutting-edge research and advanced imaging solutions to create an intuitive computer-aided diagnosis (CADx) workstation. In research settings, QuantX has been shown to increase both the efficiency and accuracy of breast cancer diagnosis. QI is pre-revenue, with first sales expected immediately following FDA clearance.

QI’s first product has been submitted for FDA review and the company is now positioned to launch its flagship product in the US and select global markets. QI is actively recruiting the industry’s influencers to work with them in their Early Adopter Program (EAP) to redefine the way MR imaging is utilized in the diagnosis and treatment of breast cancer. QI’s team includes technology leaders, innovators, and entrepreneurs, who have a history of successful fundraising, company formation, and successful exit.

QI’s management team and advisors have been responsible for many of the transformative changes in the CAD industry over the past few decades. They have taken CAD products to market, have led definitive clinical trials in the imaging industry and have worked to help redefine CAD standards.